Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 10/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6152702 | 0.98 | ADH5 (0.87) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL27893085 | 0.98 | ADH5 (0.87) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL17630068 | 0.95 | ADH5 (1.00) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL364087 | 0.91 | ADH5 (0.75) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL10574724 | 0.87 | CYP3A4 (0.74) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL3259453 | 0.86 | ADH5 (0.69) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL608826 | 0.84 | ADH5 (0.67) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL9812373 | 0.84 | ADH5 (0.66) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL3097162 | 0.84 | CYP3A4 (0.70) | ADH5CYP3A4BAZ2BHTTHTR2A | |
| SCHEMBL1274293 | 0.84 | CYP3A4 (0.70) | ADH5CYP3A4BAZ2BHTTHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930672-A | Small molecular ionic liquid monomer adhesive and preparation method thereof | 中国人民解放军国防科技大学 | 2025-05-06 | — | — | CN | claimed |
| CN-119061731-A | Antibacterial air filter paper and preparation method thereof | 南玻院(宿迁)新材料有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-117000049-A | Corrosion-resistant ultrafiltration membrane and manufacturing method thereof | 率氢技术(北京)股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-115206688-A | Preparation method and application of nano metal phosphide | 中国石油大学(华东) | 2022-10-18 | — | — | CN | claimed |
| CN-114507358-A | Method for preparing two-dimensional metal organic framework nano material by taking graphene as template | 中国石油大学(华东) | 2022-05-17 | — | — | CN | claimed |
| CN-108546332-B | Novel cadmium-metal organic framework material and preparation method and application thereof | 安徽师范大学 | 2020-09-08 | — | — | CN | claimed |
| CN-104804730-A | Fluorescent material and preparation method thereof | CHANGCHUN APPLIED CHEMISTRY | 2015-07-29 | — | — | CN | claimed |
| CN-101863894-A | Tanshinone II A derivative and preparation method and application thereof | GUANGDONG PHARMACEUTICAL UNIVERSITY | 2010-10-20 | — | — | CN | claimed |
| EP-0169164-B1 | IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-31 | — | — | EP | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119930672-A | Small molecular ionic liquid monomer adhesive and preparation method thereof | 中国人民解放军国防科技大学 | 2025-05-06 | — | — | CN | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-4963677-A | TREATMENT OF CONGESTIVE HEART FAILURE | ORION CORPORATION LTD. (FI) | 1990-10-16 | — | — | US | disclosed |
| EP-0169164-B1 | IMIDAZOLONECARBONYLARYLIMIDAZOLES; METHOD OF MANUFACTURE, METHOD OF USE AND COMPOSITIONS USEFUL THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0322746-A1 | Heterocyclic compounds | ORION CORPORATION LIMITED (FI) | 1989-07-05 | — | — | EP | disclosed |
| US-4709043-A | Process for the preparation of imidazolonecarbonylarylimidazoles | SCHERING A.G. (DE) | 1987-11-24 | — | — | US | disclosed |
| EP-0169164-A1 | Imidazolonecarbonylarylimidazoles; method of manufacture, method of use and compositions useful thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-01-22 | — | — | EP | disclosed |
| US-4556665-A | Cardiotonic 1,3-dihydro-4-[[(imidazol-1-yl)aryl]carbonyl]imidazol-2-ones | SCHERING A.G. (DE) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | ADH5 43/4885CYP3A4 697/4885BAZ2B 3907/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ADH5 1092/4885CYP3A4 24/4885BAZ2B 615/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | ADH5 3652/4885CYP3A4 3234/4885BAZ2B 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.